# NCT03391869 (NCT03391869)

> Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03391869
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Lung Adenocarcinoma; Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
- Interventions: Ipilimumab; Local Consolidation Therapy; Nivolumab; Quality-of-Life Assessment; Radiation Therapy; Therapeutic Conventional Surgery
- Enrollment: 339
- Primary outcome: Overall survival (OS) in overall population
- Primary outcome: OS in oligometastatic subgroup

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 18
- YouTube: 5
- Podcasts: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03391869

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03391869", "email": "<work email>"}; the inbox owner confirms by the emailed link.